Sovran Advisors LLC acquired a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,282 shares of the company's stock, valued at approximately $472,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DVA. UMB Bank n.a. raised its holdings in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares during the period. Copia Wealth Management purchased a new stake in shares of DaVita in the fourth quarter worth approximately $30,000. National Pension Service increased its holdings in DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after purchasing an additional 84 shares during the period. Y.D. More Investments Ltd purchased a new position in DaVita during the 1st quarter worth $35,000. Finally, NewEdge Advisors LLC increased its holdings in DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock worth $78,000 after purchasing an additional 88 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
DVA has been the subject of a number of recent analyst reports. Bank of America lowered their price objective on DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a research report on Wednesday, September 10th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Truist Financial set a $148.00 price target on DaVita in a research report on Friday, August 8th. Finally, Barclays lowered their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DaVita currently has an average rating of "Reduce" and a consensus target price of $158.00.
Read Our Latest Stock Analysis on DVA
Insider Buying and Selling
In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by company insiders.
DaVita Stock Up 1.9%
Shares of NYSE DVA traded up $2.56 during mid-day trading on Tuesday, hitting $133.71. The company had a trading volume of 84,412 shares, compared to its average volume of 857,611. The company has a market capitalization of $9.56 billion, a PE ratio of 13.14, a price-to-earnings-growth ratio of 0.93 and a beta of 1.13. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The business's 50-day simple moving average is $136.91 and its 200 day simple moving average is $140.91.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company's revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period last year, the firm earned $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Stories
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
